{
    "2018-07-02": [
        [
            {
                "time": "2018-06-01",
                "original_text": "Analysts’ Estimates and Recommendations for Eli Lilly in June",
                "features": {
                    "keywords": [
                        "Analysts’ Estimates",
                        "Recommendations",
                        "Eli Lilly"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-06-01",
                "original_text": "Eli Lilly’s Animal Health Business",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Animal Health",
                        "Business"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "animal health"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-01",
                "original_text": "Eli Lilly’s Cardiovascular Product Portfolio",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Cardiovascular",
                        "Product Portfolio"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "cardiovascular"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-01",
                "original_text": "Blog Exposure - Eli Lilly's Taltz(R) Meets Primary Endpoint in Phase-3 Study for Treatment of Ankylosing Spondylitis",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Taltz(R)",
                        "Phase-3 Study",
                        "Ankylosing Spondylitis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}